Do analysts recommend AIFF or ACON?

Aclarion has a consensus target price of $7.50, suggesting a potential upside of 181.95%. Given Aclarion's stronger consensus rating and higher probable upside, analysts clearly believe Aclarion is more favorable than Firefly Neuroscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Firefly Neuroscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend ITOC or ACON?

Aclarion has a consensus price target of $7.50, indicating a potential upside of 181.95%. Given Aclarion's stronger consensus rating and higher possible upside, analysts plainly believe Aclarion is more favorable than Itonic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Itonic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, ITOC or ACON?

Itonic has higher revenue and earnings than Aclarion. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Itonic $520K 8.85 -$5.10M N/A N/A Aclarion $83.77K 91.51 -$7.23M -$7.40 N/A

Is ITOC or ACON more profitable?

Itonic has a net margin of 0.00% compared to Aclarion's net margin of -10,948.81%. Itonic's return on equity of 0.00% beat Aclarion's return on equity. Company Net Margins Return on Equity Return on Assets Itonic N/A N/A N/A Aclarion -10,948.81% -59.34% -56.12%

Does the media prefer ITOC or ACON?

In the previous week, Itonic had 4 more articles in the media than Aclarion. MarketBeat recorded 10 mentions for Itonic and 6 mentions for Aclarion. Aclarion's average media sentiment score of 1.28 beat Itonic's score of -0.05 indicating that Aclarion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Itonic 0 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aclarion 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate HCTI or ACON?

Aclarion has a consensus target price of $7.50, suggesting a potential upside of 181.95%. Given Aclarion's stronger consensus rating and higher possible upside, analysts plainly believe Aclarion is more favorable than Healthcare Triangle. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Healthcare Triangle 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to HCTI or ACON?

In the previous week, Aclarion had 1 more articles in the media than Healthcare Triangle. MarketBeat recorded 6 mentions for Aclarion and 5 mentions for Healthcare Triangle. Aclarion's average media sentiment score of 1.28 beat Healthcare Triangle's score of -0.64 indicating that Aclarion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Healthcare Triangle 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Aclarion 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PTHL or ACON?

Aclarion has a consensus price target of $7.50, suggesting a potential upside of 181.95%. Given Aclarion's stronger consensus rating and higher probable upside, analysts clearly believe Aclarion is more favorable than Pheton. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, PTHL or ACON?

Pheton has higher revenue and earnings than Aclarion. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pheton $305.22K 6.29 -$660K N/A N/A Aclarion $83.77K 91.51 -$7.23M -$7.40 N/A

Is PTHL or ACON more profitable?

Pheton has a net margin of 0.00% compared to Aclarion's net margin of -10,948.81%. Pheton's return on equity of 0.00% beat Aclarion's return on equity. Company Net Margins Return on Equity Return on Assets Pheton N/A N/A N/A Aclarion -10,948.81% -59.34% -56.12%

Do analysts rate ACON or VSEE?

Aclarion currently has a consensus target price of $7.50, indicating a potential upside of 181.95%. Given Aclarion's stronger consensus rating and higher possible upside, equities research analysts clearly believe Aclarion is more favorable than VSee Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 VSee Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ACON or VSEE more profitable?

VSee Health has a net margin of -92.36% compared to Aclarion's net margin of -10,948.81%. Aclarion's return on equity of -59.34% beat VSee Health's return on equity. Company Net Margins Return on Equity Return on Assets Aclarion -10,948.81% -59.34% -56.12% VSee Health -92.36% -11,636.34% -68.62%

Aclarion (ACON) Competitors

$2.66 -0.05 (-1.85%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$2.62 -0.04 (-1.50%)

As of 08/24/2026 07:06 PM Eastern

Compare

ACON vs. AIFF, ITOC, HCTI, PTHL, and VSEE

Should you buy Aclarion stock or one of its competitors? Aclarion's main competitors and comparable companies include Firefly Neuroscience (AIFF), Itonic (ITOC), Healthcare Triangle (HCTI), Pheton (PTHL), and VSee Health (VSEE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Aclarion compare to Firefly Neuroscience?

Firefly Neuroscience (NASDAQ:AIFF) and Aclarion (NASDAQ:ACON) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

5.0% of Firefly Neuroscience shares are held by institutional investors. Comparatively, 7.5% of Aclarion shares are held by institutional investors. 6.9% of Firefly Neuroscience shares are held by insiders. Comparatively, 0.0% of Aclarion shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Aclarion has a consensus target price of $7.50, suggesting a potential upside of 181.95%. Given Aclarion's stronger consensus rating and higher probable upside, analysts clearly believe Aclarion is more favorable than Firefly Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Firefly Neuroscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aclarion has lower revenue, but higher earnings than Firefly Neuroscience. Firefly Neuroscience is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Firefly Neuroscience	$1.14M	14.31	-$19.88M	-$0.59	N/A
Aclarion	$83.77K	91.51	-$7.23M	-$7.40	N/A

Firefly Neuroscience has a net margin of -506.23% compared to Aclarion's net margin of -10,948.81%. Aclarion's return on equity of -59.34% beat Firefly Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Firefly Neuroscience	-506.23%	-90.17%	-72.05%
Aclarion	-10,948.81%	-59.34%	-56.12%

Firefly Neuroscience has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Aclarion has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market.

In the previous week, Aclarion had 6 more articles in the media than Firefly Neuroscience. MarketBeat recorded 6 mentions for Aclarion and 0 mentions for Firefly Neuroscience. Aclarion's average media sentiment score of 1.28 beat Firefly Neuroscience's score of 0.00 indicating that Aclarion is being referred to more favorably in the news media.

Company	Overall Sentiment
Firefly Neuroscience	Neutral
Aclarion	Positive

Summary

Aclarion beats Firefly Neuroscience on 12 of the 16 factors compared between the two stocks.

How does Aclarion compare to Itonic?

Itonic (NASDAQ:ITOC) and Aclarion (NASDAQ:ACON) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

Aclarion has a consensus price target of $7.50, indicating a potential upside of 181.95%. Given Aclarion's stronger consensus rating and higher possible upside, analysts plainly believe Aclarion is more favorable than Itonic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Itonic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Itonic had 4 more articles in the media than Aclarion. MarketBeat recorded 10 mentions for Itonic and 6 mentions for Aclarion. Aclarion's average media sentiment score of 1.28 beat Itonic's score of -0.05 indicating that Aclarion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Itonic	0 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aclarion	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Itonic has a beta of 2.81, suggesting that its stock price is 181% more volatile than the broader market. Comparatively, Aclarion has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market.

7.5% of Aclarion shares are held by institutional investors. 0.0% of Aclarion shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Itonic has higher revenue and earnings than Aclarion.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Itonic	$520K	8.85	-$5.10M	N/A	N/A
Aclarion	$83.77K	91.51	-$7.23M	-$7.40	N/A

Itonic has a net margin of 0.00% compared to Aclarion's net margin of -10,948.81%. Itonic's return on equity of 0.00% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Itonic	N/A	N/A	N/A
Aclarion	-10,948.81%	-59.34%	-56.12%

Summary

Itonic and Aclarion tied by winning 7 of the 14 factors compared between the two stocks.

How does Aclarion compare to Healthcare Triangle?

Healthcare Triangle (NASDAQ:HCTI) and Aclarion (NASDAQ:ACON) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

In the previous week, Aclarion had 1 more articles in the media than Healthcare Triangle. MarketBeat recorded 6 mentions for Aclarion and 5 mentions for Healthcare Triangle. Aclarion's average media sentiment score of 1.28 beat Healthcare Triangle's score of -0.64 indicating that Aclarion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Healthcare Triangle	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Aclarion	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aclarion has lower revenue, but higher earnings than Healthcare Triangle. Aclarion is trading at a lower price-to-earnings ratio than Healthcare Triangle, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Healthcare Triangle	$25.67M	0.49	-$9.48M	-$33.52	N/A
Aclarion	$83.77K	91.51	-$7.23M	-$7.40	N/A

0.3% of Healthcare Triangle shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 0.1% of Healthcare Triangle shares are owned by insiders. Comparatively, 0.0% of Aclarion shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Aclarion has a consensus target price of $7.50, suggesting a potential upside of 181.95%. Given Aclarion's stronger consensus rating and higher possible upside, analysts plainly believe Aclarion is more favorable than Healthcare Triangle.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Healthcare Triangle	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Healthcare Triangle has a net margin of -66.85% compared to Aclarion's net margin of -10,948.81%. Aclarion's return on equity of -59.34% beat Healthcare Triangle's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Healthcare Triangle	-66.85%	-125.45%	-36.06%
Aclarion	-10,948.81%	-59.34%	-56.12%

Healthcare Triangle has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, Aclarion has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

Summary

Aclarion beats Healthcare Triangle on 11 of the 16 factors compared between the two stocks.

How does Aclarion compare to Pheton?

Pheton (NASDAQ:PTHL) and Aclarion (NASDAQ:ACON) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Pheton has a net margin of 0.00% compared to Aclarion's net margin of -10,948.81%. Pheton's return on equity of 0.00% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pheton	N/A	N/A	N/A
Aclarion	-10,948.81%	-59.34%	-56.12%

Aclarion has a consensus price target of $7.50, suggesting a potential upside of 181.95%. Given Aclarion's stronger consensus rating and higher probable upside, analysts clearly believe Aclarion is more favorable than Pheton.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Aclarion had 6 more articles in the media than Pheton. MarketBeat recorded 6 mentions for Aclarion and 0 mentions for Pheton. Aclarion's average media sentiment score of 1.28 beat Pheton's score of 0.00 indicating that Aclarion is being referred to more favorably in the news media.

Company	Overall Sentiment
Pheton	Neutral
Aclarion	Positive

Pheton has higher revenue and earnings than Aclarion.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pheton	$305.22K	6.29	-$660K	N/A	N/A
Aclarion	$83.77K	91.51	-$7.23M	-$7.40	N/A

Pheton has a beta of 5.4, meaning that its stock price is 440% more volatile than the broader market. Comparatively, Aclarion has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market.

Summary

Aclarion beats Pheton on 8 of the 14 factors compared between the two stocks.

How does Aclarion compare to VSee Health?

Aclarion (NASDAQ:ACON) and VSee Health (NASDAQ:VSEE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

In the previous week, Aclarion had 6 more articles in the media than VSee Health. MarketBeat recorded 6 mentions for Aclarion and 0 mentions for VSee Health. Aclarion's average media sentiment score of 1.28 beat VSee Health's score of 0.00 indicating that Aclarion is being referred to more favorably in the media.

Company	Overall Sentiment
Aclarion	Positive
VSee Health	Neutral

Aclarion has higher earnings, but lower revenue than VSee Health. Aclarion is trading at a lower price-to-earnings ratio than VSee Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$83.77K	91.51	-$7.23M	-$7.40	N/A
VSee Health	$14.46M	0.01	-$14.71M	-$0.37	N/A

7.5% of Aclarion shares are owned by institutional investors. Comparatively, 1.0% of VSee Health shares are owned by institutional investors. 0.0% of Aclarion shares are owned by company insiders. Comparatively, 14.9% of VSee Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Aclarion currently has a consensus target price of $7.50, indicating a potential upside of 181.95%. Given Aclarion's stronger consensus rating and higher possible upside, equities research analysts clearly believe Aclarion is more favorable than VSee Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
VSee Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

VSee Health has a net margin of -92.36% compared to Aclarion's net margin of -10,948.81%. Aclarion's return on equity of -59.34% beat VSee Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,948.81%	-59.34%	-56.12%
VSee Health	-92.36%	-11,636.34%	-68.62%

Summary

Aclarion beats VSee Health on 10 of the 15 factors compared between the two stocks.

Get Aclarion News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACON vs. The Competition

Export

Metric	Aclarion	Healthcare Technology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.81M	$1.72B	$7.36B	$12.81B
Dividend Yield	N/A	4.69%	2.54%	10.79%
P/E Ratio	-0.36	21.28	270.59	24.05
Price / Sales	91.51	79.57	646.86	105.00
Price / Cash	N/A	31.69	29.03	36.89
Price / Book	0.18	5.82	11.17	6.40
Net Income	-$7.23M	-$18.66M	$3.46B	$347.95M
7 Day Performance	2.31%	1.02%	1.74%	1.48%
1 Month Performance	9.92%	12.71%	7.34%	5.13%
1 Year Performance	-63.39%	-16.23%	26.14%	17.00%

Aclarion Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACON Aclarion	4.1691 of 5 stars	$2.66 -1.8%	$7.50 +182.0%	-63.6%	$7.81M	$83.77K	N/A	7	Positive News Gap Up
AIFF Firefly Neuroscience	0.2855 of 5 stars	$1.09 -3.5%	N/A	-60.2%	$17.10M	$1.14M	N/A	N/A
ITOC Itonic	0.6651 of 5 stars	$0.28 +3.3%	N/A	N/A	$5.34M	$520K	N/A	N/A	Gap Down
HCTI Healthcare Triangle	0.5762 of 5 stars	$1.07 -9.3%	N/A	-99.5%	$2.45M	$13.89M	N/A	80
PTHL Pheton	N/A	$0.28 -11.9%	N/A	-51.4%	$1.82M	$305.22K	N/A	11	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACON) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aclarion (ACON) Competitors

ACON vs. AIFF, ITOC, HCTI, PTHL, and VSEE

How does Aclarion compare to Firefly Neuroscience?

Summary

How does Aclarion compare to Itonic?

Summary

How does Aclarion compare to Healthcare Triangle?

Summary

How does Aclarion compare to Pheton?

Summary

How does Aclarion compare to VSee Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACON vs. The Competition

Aclarion Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aclarion (ACON) Competitors

ACON vs. AIFF, ITOC, HCTI, PTHL, and VSEE

How does Aclarion compare to Firefly Neuroscience?

Do insiders & institutionals hold more shares of AIFF or ACON?

Do analysts recommend AIFF or ACON?

Which has higher earnings & valuation, AIFF or ACON?

Is AIFF or ACON more profitable?

Which has more volatility & risk, AIFF or ACON?

Does the media prefer AIFF or ACON?

Summary

How does Aclarion compare to Itonic?

Do analysts recommend ITOC or ACON?

Does the media prefer ITOC or ACON?

Which has more risk and volatility, ITOC or ACON?

Do insiders and institutionals hold more shares of ITOC or ACON?

Which has preferable valuation & earnings, ITOC or ACON?

Is ITOC or ACON more profitable?

Summary

How does Aclarion compare to Healthcare Triangle?

Does the media refer more to HCTI or ACON?

Which has preferable earnings & valuation, HCTI or ACON?

Do insiders & institutionals hold more shares of HCTI or ACON?

Do analysts rate HCTI or ACON?

Is HCTI or ACON more profitable?

Which has more risk and volatility, HCTI or ACON?

Summary

How does Aclarion compare to Pheton?

Is PTHL or ACON more profitable?

Do analysts rate PTHL or ACON?

Does the media prefer PTHL or ACON?

Which has stronger valuation & earnings, PTHL or ACON?

Do institutionals and insiders hold more shares of PTHL or ACON?

Which has more volatility and risk, PTHL or ACON?

Summary

How does Aclarion compare to VSee Health?

Does the media prefer ACON or VSEE?

Which has preferable valuation and earnings, ACON or VSEE?

Do insiders and institutionals believe in ACON or VSEE?

Do analysts rate ACON or VSEE?

Is ACON or VSEE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACON vs. The Competition

Aclarion Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools